Statistics
Publications
14
Citations
1.3K
H-Index
13
Active since
2012
Richard Zang is an author at Novartis (United States) specializing in molecular oncology, pharmacology, and oncology.
Publications per year
2012–2023
14
14
Antibody Conjugation of a Chimeric BET Degrader Enables <i>in vivo</i> Activity
Thomas H. Pillow, Pragya Adhikari, Robert A. Blake et al. · ChemMedChem · 2019 · 196 citations
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
Pablo D. García, John L. Langowski, Yingyun Wang et al. · Clinical Cancer Research · 2014 · 111 citations · Full text
Medicine, Oncology, Pharmacology +17
1–5 of 14